1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
Delayed Nasdaq  -  04:00 2022-07-01 pm EDT
180.11 USD   +1.79%
07/02Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer
BU
07/02Seagen Inc. Announces Full Results from the Pivotal Phase 2 MOUNTAINEER Trial, Which Showed TUKYSA in Combination with Trastuzumab
CI
07/01INSIDER SELL : Seagen
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
177.73(c) 178.47(c) 179.06(c) 176.94(c) 180.11(c) Last
1 192 439 1 468 981 1 150 018 1 232 598 958 533 Volume
-0.89% +0.42% +0.33% -1.18% +1.79% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1 787 M - -
Net income 2022 -653 M - -
Net cash position 2022 1 615 M - -
P/E ratio 2022 -52,0x
Yield 2022 -
Sales 2023 2 480 M - -
Net income 2023 -221 M - -
Net cash position 2023 1 835 M - -
P/E ratio 2023 -147x
Yield 2023 -
Capitalization 33 154 M 33 154 M -
EV / Sales 2022 17,7x
EV / Sales 2023 12,6x
Nbr of Employees 2 675
Free-Float 99,2%
More Financials
Company
Seagen Inc. specializes in the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. Net sales break down by source of income as follows: - product sales (88%); - royalties (9.6%); - licenses and collaboration agreements (2.4%). 
More about the company
Ratings of Seagen Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about SEAGEN INC.
07/02Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meanin..
BU
07/02Seagen Inc. Announces Full Results from the Pivotal Phase 2 MOUNTAINEER Trial, Which Sh..
CI
07/01INSIDER SELL : Seagen
MT
06/29Raymond James Starts Seagen at Outperform With $220 Price Target
MT
06/24BMO Capital Starts Seagen at Market Perform With $169 Price Target
MT
06/24SEAGEN INC.(NASDAQGS : SGEN) dropped from Russell 3000 Value Index
CI
06/24SEAGEN INC.(NASDAQGS : SGEN) dropped from Russell Midcap Value Index
CI
06/24SEAGEN INC.(NASDAQGS : SGEN) dropped from Russell 3000E Value Index
CI
06/24SEAGEN INC.(NASDAQGS : SGEN) dropped from Russell Small Cap Comp Value Index
CI
06/24SEAGEN INC.(NASDAQGS : SGEN) dropped from Russell 1000 Value Index
CI
06/23Merck Reportedly Pushes Forward with Potential Deal for Seagen
CI
06/21Oppenheimer Adjusts Seagen Price Target to $208 From $160, Maintains Outperform Rating
MT
06/17US Stocks Mixed on Friday as Fed's Powell Reiterates Focus on Containing Inflation
MT
06/17US Stocks Mixed on Friday as Powell Reiterates Focus on Containing Inflation
MT
06/17Adobe, Devon Energy fall; Moderna, Seagen rise
AQ
More news
News in other languages on SEAGEN INC.
07/02Seagen Inc. annonce les résultats complets de l'essai pivot de phase 2 MOUNTAINEER, qui..
06/24Wall Street finit en hausse, moins anxieuse d'une récession et de l'inflation
06/24MÄRKTE USA/Börsen kräftig rauf - Hoffnung auf weniger harsche Fed
06/24Wall Street positief richting weekend
06/24Wall Street koerst flink hoger
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 180,11 $
Average target price 168,40 $
Spread / Average Target -6,50%
EPS Revisions
Managers and Directors
Roger D. Dansey Chief Executive & Medical Officer
Todd E. Simpson Chief Financial Officer
Felix James Baker Chairman
Vaughn B. Himes Chief Technical Officer
David W. Gryska Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.16.50%33 154
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.83%40 011
CELLTRION, INC.-9.60%19 031
ALNYLAM PHARMACEUTICALS, INC.-12.58%17 911